<code id='90A8CDB022'></code><style id='90A8CDB022'></style>
    • <acronym id='90A8CDB022'></acronym>
      <center id='90A8CDB022'><center id='90A8CDB022'><tfoot id='90A8CDB022'></tfoot></center><abbr id='90A8CDB022'><dir id='90A8CDB022'><tfoot id='90A8CDB022'></tfoot><noframes id='90A8CDB022'>

    • <optgroup id='90A8CDB022'><strike id='90A8CDB022'><sup id='90A8CDB022'></sup></strike><code id='90A8CDB022'></code></optgroup>
        1. <b id='90A8CDB022'><label id='90A8CDB022'><select id='90A8CDB022'><dt id='90A8CDB022'><span id='90A8CDB022'></span></dt></select></label></b><u id='90A8CDB022'></u>
          <i id='90A8CDB022'><strike id='90A8CDB022'><tt id='90A8CDB022'><pre id='90A8CDB022'></pre></tt></strike></i>

          leisure time

          leisure time

          author:focus    Page View:64738
          Damian Garde of STAT talks with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho at STAT in NYC.
          Damian Garde of STAT, left, talked with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho about the GLP-1 weight loss market. Michelle C. Gevint for STAT

          NEW YORK — Will the world actually soon spend $100 billion a year on the new obesity medicines?

          Plenty of people in pharma and at the banks that invest in it seem to think so. Goldman Sachs, Barclays, BMO Capital Markets and Pfizer have all arrived at the glossy, cut-for-headline number for spending by around 2030.

          advertisement

          Yet Jared Holz, a healthcare strategist at Mizuho, is skeptical. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Wikipedia

          After affirmative action ruling, medical educators look to 'holistic review'
          After affirmative action ruling, medical educators look to 'holistic review'

          AnnaMoneymaker/GettyImagesAfterhavingadaytoreadthroughtheSupremeCourt’sdecisiononaffirmativeaction,s

          read more
          Asahi Kasei to buy Calliditas, picking up kidney disease drug
          Asahi Kasei to buy Calliditas, picking up kidney disease drug

          AdobeLONDON—Seekingtobuildupitspharmabusiness,theJapaneseconglomerateAsahiKaseiismovingtobuySwedishb

          read more
          How to save PrEP access — and even expand it
          How to save PrEP access — and even expand it

          UndertheAffordableCareAct,healthinsurersarerequiredtocoverallcostsassociatedwithpreventivecare—inclu

          read more

          Congress: Prevent baby formula shortages by passing a new bill

          ScottOlson/GettyImagesFamiliesinAmericashouldneverhavetoscroungeforbabyformula.TheUnitedStatesneedsa